M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 6.42 USD Market Closed
Market Cap: 216.3m USD
Have any thoughts about
Myomo Inc?
Write Note

Myomo Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Myomo Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Net Issuance of Common Stock
$5.4m
CAGR 3-Years
-14%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Net Issuance of Common Stock
-$500m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Boston Scientific Corp
NYSE:BSX
Net Issuance of Common Stock
$219m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Net Issuance of Common Stock
-$966m
CAGR 3-Years
9%
CAGR 5-Years
-161%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Issuance of Common Stock
$345.3m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Myomo Inc
Glance View

Market Cap
216.3m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
3.85 USD
Overvaluation 40%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
5.4m USD

Based on the financial report for Sep 30, 2024, Myomo Inc's Net Issuance of Common Stock amounts to 5.4m USD.

What is Myomo Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-1%

Over the last year, the Net Issuance of Common Stock growth was -47%. The average annual Net Issuance of Common Stock growth rates for Myomo Inc have been -14% over the past three years , -1% over the past five years .

Back to Top